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Under the selective pressure of protease inhibitor therapy, patients infected with human immunodeficiency
virus (HIV) often develop drug-resistant HIV strains. One of the first drug-resistant mutations to arise in the
protease, particularly in patients receiving indinavir or ritonavir treatment, is V82A, which compromises the
binding of these and other inhibitors but allows the virus to remain viable. To probe this drug resistance, we
solved the crystal structures of three natural substrates and two commercial drugs in complex with an inactive
drug-resistant mutant (D25N/V82A) HIV-1 protease. Through structural analysis and comparison of the
protein-ligand interactions, we found that Val82 interacts more closely with the drugs than with the natural
substrate peptides. The V82A mutation compromises these interactions with the drugs while not greatly
affecting the substrate interactions, which is consistent with previously published kinetic data. Coupled with
our earlier observations, these findings suggest that future inhibitor design may reduce the probability of the
appearance of drug-resistant mutations by targeting residues that are essential for substrate recognition.
The development of the human immunodeficiency virus type
1 (HIV-1) protease inhibitors is regarded as a major success of
structure-based drug design (16, 36, 62–64). Indeed, the pro-
tease inhibitors are considered the most potent drugs currently
available for the treatment of AIDS (63). These drugs are
often combined with other drugs to establish highly active
antiretroviral therapy, which is credited with an approximately
threefold drop in the death rate from AIDS since its introduc-
tion (38). Despite this remarkable success, the emergence of
HIV-1 mutants that resist current drug regimes (1, 2, 14) re-
mains a critical factor in clinical failure of antiviral therapy (9,
56). The relatively rapid appearance of resistant viral mutants
among treated HIV-1 patients is attributable to the high rate of
replication of the virus, coupled with a high intrinsic rate of
mutation due to the infidelity of the HIV-1 reverse transcrip-
tase (22, 46, 47).
The homodimeric HIV-1 protease is an effective therapeutic
target because it allows viral maturation by sequentially cleav-
ing at least 10 asymmetric and nonhomologous sequences in
the Gag-Pol polyproteins (8, 19, 42). The six Food and Drug
Administration-approved HIV-1 protease inhibitors, amprena-
vir (APV), indinavir (IDV), nelfinavir (NFV), saquinavir
(SQV), ritonavir (RTV), and lopinavir (LPV), that are on the
market are all competitive inhibitors (17), binding at the active
site. Therefore, they compete directly with the enzyme’s ability
to recognize substrates (33, 34, 43, 44, 49, 60). These drugs are
peptidomimetics that resulted from structure-based drug de-
sign efforts (7, 23–25, 55, 59). All of them have large, generally
hydrophobic moieties that interact with the mainly hydropho-
bic S2-S2 pockets in the active site (62). Despite chemical
differences, these inhibitors occupy a similar space in the active
site, and hence similar mutations in HIV-1 protease can cause
multidrug resistance without substantially altering substrate
binding (1, 45, 51).
Since the primary function of HIV-1 protease is to cleave its
substrates rather than bind inhibitors, our laboratory analyzed
the substrate recognition of this enzyme and attempted to
arrive at a structural rationale for what constitutes a substrate.
We determined the crystal structures of peptides bound to an
inactive wild-type HIV-1 protease (44). Analysis of these com-
plexes found that all the conserved protease-substrate hydro-
gen bonds involve only backbone atoms of the substrate and
therefore are unlikely to be the primary determinant of sub-
strate specificity; also, the conformation of the unprimed side
of the peptide is conserved and asymmetric, resembling a
toroid in the S1–S3 pockets, while the prime side of the peptide
remains extended. Based on these two observations, we pro-
posed that the major determinant of specificity for HIV-1
protease is that the conformation of the unprimed side of the
substrate can form a toroid.
To further understand the substrate binding, drug resis-
tance, and protein adaptability of HIV-1 protease (26, 43, 44,
53), we examined one of the first drug-resistant mutations to
occur in HIV-1 protease among patients receiving antiviral
therapy, V82A (54). This mutation occurs particularly in those
patients receiving IDV or RTV (9, 10, 12, 39). Structurally, the
Val82 residue is located at the P1-loops (Gly78-Asn83) near
the active site (see Fig. 1a). The effect of this mutation on the
binding to RTV, IDV, and NFV inhibitors is to significantly
reduce their affinity (18, 27), whereas in contrast, the effect of
this mutation on the ability of the enzyme to cleave substrates
is smaller (18, 27). Understanding how the drug-resistant pro-
tease recognizes both substrates and inhibitors becomes crucial
for future rational drug design. To address this issue, we have
determined the crystal structures of the inactive drug-resistant
variant D25N/V82A of HIV-1 protease in complex with either
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of three Gag peptide substrates—matrix-capsid (MA-CA),
capsid-p2 (CA-p2), and p1–p6—and two clinically used
drugs—SQV and RTV. We conducted structural analysis using
these complexes in relevance to ligand-protease interaction,
which includes shape complementarity, hydrogen bonds, van
der Waals (VDW) packing, and estimation of VDW interac-
tion energy. Since the wild-type structures for these ligands are
already available in the Protein Data Bank (7, 23–25, 55), it
allowed us to make a direct structural comparison. The find-
ings of this study suggest that Val82 is not crucial for substrate
recognition but is critical for inhibitor binding.
MATERIALS AND METHODS
Nomenclature. Ligand acronyms with corresponding subscripts, such as V82A
for the mutant or WT for wild-type protease, are used to distinguish HIV-1
protease variants throughout this article. For example, p1–p6V82A denotes p1–p6
cleavage site peptide complexed to the V82A mutant protease.
Mutagenesis, protein purification, and crystallization. The protease gene con-
taining the D25N modification was a gift from C. S. Craik, University of Cali-
fornia San Francisco; the D25N mutation is required for complexing protease
with its substrates without cleaving them. The alanine mutation at position 82
was introduced by using the QuickChange site-directed mutagenesis kit (Strat-
agene, La Jolla, Calif.). The protocol used for protein overexpression and puri-
fication has been described previously (21, 43, 48).
The purified protein was concentrated to 2.5 mg ml1 and equilibrated on ice
for 30 min with a fivefold molar excess of the ligand. Crystals were obtained in
hanging drops under more than one condition. The crystals used here were
grown with a reservoir solution of 126 mM phosphate buffer (pH 6.2), 63 mM
sodium citrate, and ammonium sulfate (28 to 31% and 22% for the substrates
and inhibitors, respectively) (43, 57). The crystals were brick shaped, tiny, and
colorless, with a maximum dimension between 0.1 and 0.2 mm; the protein
concentration ranged between 0.4 and 1.9 mg ml1.
Data collection. Intensity data were collected by using a Rigaku R-axis image
plate mounted on a Rigaku rotating-anode X-ray generator, with the latter
operating at 50 kV and 100 mA. The Yale mirror system was used to focus the
X-ray beam. Data for the CA-p2V82A, p1–p6V82A, and SQVV82A complexes were
collected at 25°C, while data for the MA-CAV82A and RTVV82A complexes were
collected at 80°C. The crystal system and cell dimensions were determined
using the program DENZO (37, 40a). Indexing of reflections revealed that
crystals for all of the complexes grew in a similar P212121 cell, except for the
RTVV82A crystals, which grew in a P21 cell with   99.8°. However, its unit cell
vectors, a, b, and c, were similar to those of the remaining complexes. The final
data collection statistics for the five structures in this study are shown in Table 1.
Structure solution and crystallographic refinement. Structure solution and
crystallographic refinement for all five structures were carried out using the
Crystallography & NMR System version 0.9 (5). A previously published inhibitor
complex (PDB:1MTR) (35) was used as the starting model for solving substrate
FIG. 1. Overall structure of the complexes. (a) Ribbon diagram of HIV-1 protease dimer (PDB code 1F7A [43]) bound to the CA-p2 substrate
highlights the position of Val82. (b) Superposition of the three substrateV82A complexes, MA-CA, CA-p2, and p1-p6, and five inhibitorWT
compounds, APV (1HPV [25]), IDV (1HSG [7]), NFV (1OHR [23]), SQV (1HXB [55]), and RTV (1HXW [24]). (c and d) Consensus volume
occupied by the three substrates (c) and the five inhibitors (d), generated using GRASP (40). The consensus volume is defined as the volume
occupied by at least two of three substrates and three of five inhibitors for the substrateV82A and inhibitorWT complexes, respectively.
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structures, while for inhibitor complexes, one of our substrateWT structures
(PDB:1F7A) (43) was utilized. This interchange of substrate structures for re-
fining inhibitor complexes and vice versa was followed to reduce model bias. For
structures whose space group is P212121, one protease dimer was used for
conducting isomorphous molecular replacement. However, for the RTVV82A
complex, whose asymmetric unit contain two dimers, the correct structure solu-
tion was arrived at by using molecular replacement techniques. The cell dimen-
sions that were originally computed for RTVV82A by DENZO exhibited a mon-
oclinic P21 cell with   99.8°; the translation solution for one of the dimers was
unambiguously obtained (1  3.0°, 2  14.4°, 3  35.7°; tx  4.5 A˚, ty  0.2
A˚, tz  14.0 A˚). By fixing the position of this dimer, the translation solution
search was repeated and the solution for the second dimer in the asymmetric unit
was also arrived at (1  180.2°, 2  77.6°, 3  178.3°; tx  14.8 A˚, ty  16.7
A˚, tz  3.4 A˚). The packing for individual dimers was approximately 35%, and
the two dimers combined yielded a packing of 65%, indicating that the struc-
ture solution has yielded reliable solutions.
The strategy used here for refining the five crystal structures has been dis-
cussed elsewhere (43, 44). Each typical cycle of refinement included positional
refinement, B-factor refinement, and visual inspection of the model in interactive
graphics using the molecular modeling package CHAIN (50). Noncrystallo-
graphic symmetry restraints were applied only between dimers of the RTVV82A
complex. No noncrystallographic symmetry restraints were imposed within the
dimers of all five complexes because they are asymmetric. Before the start of
crystallographic refinement, 10% of the reflections were set aside for cross-
validation (Rfree) purposes; throughout the entire refinement, Rfree was moni-
tored. The treatment of Rfree was carried out as elaborated in the literature (3,
28, 29). The locations of the ligands and protein were further reaffirmed by
computing simulated annealed omit maps (4, 6). Final refinement statistics are
also provided in Table 1.
Structural analysis. (i) Difference distance plots. The difference distance plots
are constructed to assess intramolecular relative shifts in response to ligand
binding (26). Initially, Ci-to-Cj distances ([dij]A) were computed between all of
the C atoms within a protease dimer of a complex, A, and repeated for a second
complex, B, with which the first structure is compared. The difference in these
distances ([Dij]  [dij]A  [dij]B) was plotted as a two-dimensional contour plot
as a function of residue numbers (i and j) by using GNUPLOT (61).
(ii) Buried surface area. The classic Lee and Richards program (31) was used
to evaluate the surface area buried by the ligands on complexation. Accessible
surface area (ASA) was computed for each of the ligand-bound protease struc-
tures. The ASA calculation was repeated for the unbound ligands in the absence
of the protease coordinates as well. The difference in these two ASA values is
defined as the surface area buried on complexation.
(iii) Shape complementarity. Besides buried surface area, another crucial
feature that has been suggested to determine the specificity and stability of
protein-ligand association is shape complementarity (SC) (30). SC is related to
the dot product of the normals of the apposing surfaces and the exponent of the
distances between them (for the complete mathematical formulation, see refer-
ence 30). The protocol includes the following: construction of molecular surface
for both ligands and protein, calculation of normal vectors (nligand and nprotein)
over a user-designated grid space, and computation of the intermolecular dis-
tance matrix between each intermolecular grid point (xligand  xprotein). The SC
by the ligand on the protein is now given by the relationship SCligand3protein 
(nligand  nprotein)exp[w(xligand  xprotein)]. The SCligandxprotein is then computed
for each grid point, summed, and averaged. The calculation is repeated to obtain
SCprotein3ligand. Finally, the average of the two SC values is the actual SC. In this
analysis, we quote SC values as SCV82A/SCWT ratios.
(iv) VDW interaction energy. Estimates of VDW interaction energy were
computed to provide a theoretical quantitative assessment for the ligand-pro-
tease nonbonded interactions. VDW energy between ith and jth atoms is calcu-
lated using the Lennard-Jones potential function. The Crystallography & NMR
System was used to perform this task; it utilizes data from reference 13 to obtain
interatomic distances and incorporates the PROLSQ REPEL function (20) for
treating nonbonded interactions.
RESULTS
Overall structural features. Three decameric substrate pep-
tides from the Gag cleavage sites of matrix-capsid (MA-CA:
VSQNY-PIVQN), capsid-p2 (CA-p2: KARVL-AEAMS) and
p1–p6 (RPGNF-LQSRP) and two protease inhibitors, SQV
and RTV, were crystallized in complex with the an inactive
(D25N) variant of HIV-1 protease with the drug resistant
V82A mutation. The crystallographic statistics for these struc-
tures are listed in Table 1. The inhibitors and the substrate
peptides were unambiguously located in the two difference
Fourier maps, 2Fo - Fc and Fo - Fc, and each of the ligands was
uniquely oriented within the protease dimer. This uniqueness
TABLE 1. Data collection and refinement statistics for the five proteaseV82A complexes
a
Variable MA-CA CA-p2 p1-p6 SQV RTV
Ligand sequence VSQNY-PIVQN KARVL-AEAMS RPGNF-LQSRP See Fig. 3 See Fig. 3
Data collection
Space group P212121 P212121 P212121 P212121 P21
a (A˚) 50.97 51.56 51.27 51.44 51.62
b (A˚) 57.86 59.38 59.13 60.04 59.04
c (A˚) 62.07 61.87 61.93 62.02 61.35
 (°) 99.8
Z 4 4 4 4 4
Temp (°C) 80 25 25 25 80
Resolution (A˚) 1.9 (1.97–1.9) 2.15 (2.23–2.15) 2.0 (2.07–2.0) 2.5 (2.59–2.5) 2.2 (2.28–2.5)
Total no. of reflections 48,168 25,200 98,506 28,072 19,193
No. of unique reflections 14,278 (1086) 10,094 (834) 12,659 (1182) 6,743 (496) 13,097 (1183)
Rmerge (%) 5.7 (19) 7.4 (31) 9.0 (33) 8.0 (36) 6.4 (27)
Completeness (%) 94.9 (74) 93.2 (76) 95.4 (92) 93.4 (71) 71.2 (66)
I/	I 5.8 7.5 7.7 7.0 7.6
Refinement
R value (%) 20.1 (26) 20.8 (32) 17.9 (22) 19.1 (30) 22.3 (32)
Rfree (%) 22.7 (32) 24.3 (34) 21.0 (29) 25.7 (36) 28.4 (37)
Sigma cutoff 0 0 0 0 0
RMSDb in:
Bond lengths (A˚) 0.005 0.006 0.005 0.008 0.008
Bond angles (°) 1.3 1.4 1.8 1.3 1.4
a Values in parentheses are the statistics corresponding to the highest-resolution shell.
b RMSD, root mean square deviation.
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in the orientation is crucial for accurately determining ligand-
protease interactions.
As in wild-type HIV-1 protease-substrate complexes (43, 44)
and protease-substrate analogue structures (33, 34, 60), the
substrate peptides in the V82A complexes also assume a rela-
tively extended conformation (Fig. 1a and b). Also preserved in
the V82A complexes is the toroid shape on the unprimed side
of the substrate (Fig. 1c). This shape is achieved by the packing
of P3 and/or P4 against the P1 side chain. In spite of having a
glycine at P3, as seen in the corresponding wild-type complex,
the p1–p6V82A peptide also forms a toroid through changes in
the peptide backbone conformation (Fig. 1b). In contrast, the
shapes of the five commercially available drugs, as observed in
the wild-type complexes (7, 23–25, 55) do not form this toroid
(Fig. 1d). Thus, the inhibitors do not mimic the conserved
structural motif exhibited by the substrate sequences.
To probe the effect of the V82A mutation, we compared the
structures of the ligandV82A complexes with their wild-type
counterparts. To elucidate the distant structural alterations
(26), difference distance plots were generated between the
V82A and wild-type structures (24, 44, 55) of each ligand (Fig.
2). The plots involving substrate structures indicate only minor
deviations (Fig. 2a and b), while the inhibitorV82A complexes,
on the other hand, exhibit substantial shifts from the corre-
sponding inhibitorWT structures, especially near the protease
flaps (Lys45-Ile54) (Fig. 2c and d). Thus, the three
substrateV82A complexes are very structurally similar to their
substrateWT complexes, while inhibitorV82A complexes are not.
Protease-ligand hydrogen bonds. In protein-ligand interac-
tions, hydrogen bonds play a crucial role in stabilizing the
complex and, in many instances, also determining specificity.
Analysis of the wild-type protease-ligand hydrogen bonds in-
volving five inhibitors and six substrates suggests that the sub-
strates form almost twice the number of hydrogen bonds with
the protease (about 16) compared with the inhibitors (about 9)
(Fig. 3a). Furthermore, the number of hydrogen bonds in each
substrateWT complex is similar to that in the substrateV82A
complexes whereas four hydrogen bonds were lost between the
inhibitorWT and inhibitorV82A complexes. This difference (Fig.
3a) indicates that the mutation has specifically affected pro-
tease-inhibitor hydrogen bonding.
As previously observed in substrateWT complexes (44), the
hydrogen bonds conserved among these three substrateV82A
complexes involve only the backbone atoms of the peptides
(Fig. 3b). Nine hydrogen bonds are conserved among the three
substrateV82A complexes, eight of which are conserved among
all six substrateWT complexes as well. Thus, the conserved
hydrogen bonding pattern present among the substrateWT
complexes is retained among the substrateV82A complexes as
well, indicating that the protease-substrate hydrogen bonding
is not perturbed by the V82A mutation.
In contrast, the inhibitorWT complexes, SQVWT and
RTVWT, make 13 and 11 protease-inhibitor hydrogen bonds,
respectively, 9 of which are conserved between them (Fig. 3c
and d). In the SQVV82A and RTVV82A complexes, however,
there are nine and seven protease-inhibitor hydrogen bonds,
respectively, five of which are conserved between them. The
catalytic aspartic acids, Asp25/25, make four hydrogen bonds
with one atom each of the inhibitor in the inhibitorWT com-
plexes, and these four hydrogen bonds are also seen in the
inhibitorV82A complexes with nearly identical interatomic dis-
tances. The conservation of these four hydrogen bonds sup-
ports the likelihood that the D25N mutation has not caused
any change in the complex. A large-scale shift that is seen in
the protease flaps (1.2 A˚ in the RTVV82A relative to the
RTVWT complex) and that is not in the proximity of Asn25/25
substantially alters hydrogen bonding patterns in the
inhibitorV82A complexes. Thus, the differences in protease-
inhibitor hydrogen bonding patterns between the inhibitorWT
and the inhibitorV82A complexes unambiguously reveal that
inhibitor binding has been substantially affected in the V82A
drug-resistant protease.
VDW interactions. The surface area buried by the ligands on
binding the protease molecule, which is an indicative parame-
ter of the extensiveness of the ligand-protein interface, was
computed by the method of Lee and Richards (31) (Table 2).
Typically, substrates buried 850 to 1000 A˚2 of their accessible
surface area while the inhibitors account for only 500 to 650
A˚2. This amounts to a 30 to 40% reduction of buried surface
area by the inhibitors relative to the substrates. Although the
change in buried surface area due to mutation is not very
significant (Table 2), the difference in area between the sub-
strates and inhibitors indicates that the substrate-protease as-
sociation is more extensive than the inhibitor-protease inter-
face.
Complementation of shape by the VDW surface of protease
residue 82 with the VDW surfaces of the ligands is likely to
provide further evidence for the influence of mutation (Fig. 4a
and b). The VDW surface of residue 82 (valine or alanine)
does not make any contact with VDW surface on the primed
side of the substrates, P1–P3 (Fig. 4a). On the unprimed side
of the peptide, however, Ala82 contacts all the substrates
tangentially while Val82 contacts only PheP1 in the p1–p6WT
complex, closely resembling the pattern observed in the p1–
p6V82A complex. While the SQVWT and RTVWT complexes
exhibit a high degree of packing between the VDW surfaces of
the inhibitor and Val82/82 (Fig. 4b), the VDW surfaces of
both Ala82 and Ala82 fail to contact those of the inhibitor in
the SQVV82A and RTVV82A complexes (Fig. 4b).
In particular, VDW packing in the RTVWT complex is
achieved by both side chain atoms of Val82, CG1 and CG2,
contacting the isopropyl group of the 2-isopropyl-4-thiazolyl at
the P3 position of the drug. In addition, the isopropyl group
extends the farthest at this site compared with any drug or
substrate probed in this investigation (Fig. 1b). This isopropyl
group appears to have been designed to target the pocket by
the Val82 residue, and when an alanine mutation occurs, the
P3 group is no longer complementary (Fig. 4b).
SQV, on the other hand, due to its similarities to the natu-
rally occurring substrates, at least in the P2–P2 region (Fig.
1b), is less vulnerable to V82A mutation. In fact, the computed
shape complementarity (30) decreases by only 18% in SQV
compared with 28% in RTV for the inhibitorV82A relative to
corresponding wild-type complexes. However, with the excep-
tion of the MA-CA complexes, the substrate-protease shape
complementarity between the wild type and V82A are very
similar (Table 2).
The effect of mutation was further investigated by comput-
ing ligand-protease VDW interaction energy (Table 2). A com-
parison of the estimated VDW interaction energy between the
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wild-type and V82A substrate structures shows a difference of
less than 1.5 kcal/mol. The SQVV82A complex, surprisingly,
decreased VDW interaction energy by approximately 12 kcal/
mol. However, this is probably because SQVWT complex (55)
was refined with an earlier force field in X-PLOR 2.1 and even
small differences in VDW radii can lead to substantial differ-
ences in the estimates of energies if different force fields are
used. In the RTVV82A structure, where the refinement force
field is the same for as that used to refine the RTVWT complex
(24), the increase in computed VDW interaction energy, by
nearly 10 kcal/mol, indicates that RTVV82A is less favorable
than the RTVWT complex.
FIG. 2. Double difference plots. Relative shifts in the V82A complexes in reference to the corresponding wild-type complexes. (a) CA-p2; (b)
p1-p6; (c) SQV; (d) RTV. Each contour line represents a deviation by 0.25 A˚. The different colors black, green, red, and blue distinguish the
contour ranges 1.0 A˚ and below, 0.5 to 1.0 A˚, 1.0 A˚ and above, and 0.5 to 1.0 A˚, respectively.
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The number of substrate atoms within a VDW radius of
residue 82 was compared in nine substrate complexes (three
substrateV82A and six substrateWT complexes [43, 44]) and
seven inhibitor structures (two inhibitorV82A and five inhibi-
torWT structures [7, 23–25, 55]) (Fig. 4c). In all drug complexes
except APV, six or more atoms of the drug molecule surround
the side chain atoms of Val82 (Fig. 4c), explaining the impor-
tance of Val82 for inhibitor binding. In contrast, five or fewer
atoms of the substrate peptides surround Val82 in most of the
substrateWT complexes. The only substrate complex for which
this is an exception is the p1–p6WT complex, where 10 sub-
strate atoms lie within the VDW contact distance of the Val82
FIG. 3. Protease-ligand hydrogen bonds. (a) Histogram representation of numbers of protease-ligand hydrogen bonds to elucidate differences
between the substrate and inhibitor complexes. The numbers of hydrogen bonds in substrateWT and inhibitorWT complexes are in white;
substrateV82A and inhibitorV82A complexes are colored black. (b) Ball-and-stick diagram of conserved hydrogen bonds (dotted lines) among the
three substrateV82A complexes. Monomers are distinguished in black and gray, while the main-chain atoms of the CA-p2 peptide, shown as a
representative substrate, are green. In this panel and the subsequent ones, nitrogen and oxygen atoms are highlighted by small spheres. (c)
SQVV82A (black) and SQVWT (cyan): QncP3, 2-carbonylquinoline; HphP1, phenylalaninol group; DiqP1, decahydro-1-methylsoquinoline-2-
carbonyl; NtbP2, tert-butylamino group. (d) RTVV82A (black) and RTVWT (cyan): P3, 2-isopropyl-4-thiazolyl; P2, valine; P1 and P1, phenyl-
alaninol groups; P2, 5-thiazolyl.
TABLE 2. Comparison of the structural analysis performed on the five V82A complexes and their wild-type equivalentsa
Structure
Surface area buried
by ligand on
complexation (A˚2)
Ratio in shape
complementarity
V82A/WT
No. of ligand-protease
VDWb contacts
Ligand-protease
estimated VDW
interaction energy
(kcal/mole)
WT V82A WT V82A WT V82A
MA-CAc 928 867 0.83 174 (5) 159 (3) 4.6 3.5
CA-p2c 977 923 1.00 167 (1) 164 (1) 1.7 3.1
p1-p6c 1,029 1,038 1.07 197 (10) 202 (3) 0.3 0.1
SQV 612 630 0.82 165 (7) 142 (1) 18.9d 6.7
RTV 526 500 0.72 165 (11) 130 (2) 7.9 15.2
a The structural analysis includes surface area buried by the ligand on complexation, shape complementarity, number of ligand-protease VDW contacts, and ligand
protease estimated VDW interaction energy. The numbers shown in parentheses highlight the number of atoms located within VDW radius distance of residue 82 in
the corresponding structures.
b The distance criterion used for the VDW contacts is 2.4 to 4.2 A˚.
c In the comparison of the peptide complexes, only equivalent residues were used, since the termini were disordered in some of the crystal structures.
d The refinement of SQVWT was carried out using X-PLOR version 2.1 which had slightly different non-bonded energy parameters.
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FIG. 4. Protease-ligand VDW interactions. (a and b) VDW surfaces of residue 82, viewed down the dimer twofold axis, and the neighboring
atoms of the corresponding substrates (a) and inhibitors (b). The ligands and the protease are shown in gray and black, respectively. A C trace
of the overlying flaps is also shown. (c) Histogram representation of numbers of ligand atoms within VDW contact of residue 82 in the crystal
structures determined here. The number of atoms in the substrateWT and inhibitorWT complexes are shown in white, and those in the substrateV82A
and inhibitorV82A complexes are shown in black. Abbreviations are defined in the legend to Fig. 3.
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side chain. The p1–p6V82A is also the only complex where
contact of seven atoms within VDW radii of Ala82 is lost, thus
reducing the VDW interaction considerably (Fig. 4c) com-
pared with the p1–p6WT complex. However, this reduction
seems to be compensated in the p1–p6V82A complex by the
conservation of the total number of substrate-protease VDW
contacts (Table 2). This compensation is achieved by subtle
side chain alterations undergone by Asn at the P2 position of
the p1–p6 substrate in combination with slight changes in
Val32 and Ile47 of the protease. Thus, as seen in the CA-p2WT
structure (43), the protease as well as its substrates are highly
adaptable to each other.
In comparison with the inhibitorWT complexes, the
inhibitorV82A complexes have far fewer atoms making VDW
contacts with Ala82 (Fig. 4c). Only one atom comes within
VDW contact of Ala82 in the SQVV82A complex, while seven
atoms surround Val82 in the SQVWT complex. The decrease is
even larger in the RTVV82A complex, where only 2 atoms come
within the VDW distance of Ala82, while 11 atoms surround
Val82 in the RTVWT complex. This clustering of atoms around
Val82 in the inhibitor complexes suggests that the inhibitors
were designed to contact the valine residue.
As an extension to VDW contacts by Val82 (or Ala82) with
ligands, assessment of VDW contacts between the ligands and
the entire protein is also crucial. The change in the number of
substrate-protease VDW contacts was either absent (as in
Ca-p2 and p1–p6) or nominal (as in MA-CA) (Table 2). How-
ever, significant loss in the number of inhibitor-protease VDW
contacts was observed between the SQV complexes (165 in
SQVWT and 142 in SQVV82A) (Table 2) and the RTV com-
plexes (165 in RTVWT and 130 in RTVV82A). Thus, the overall
effect of V82A mutation in the substrate complexes is minimal
compared to its affect on the inhibitor complexes.
DISCUSSION
Our results reveal high structural similarity among the three
V82A substrate complexes, CA-p2V82A, p1–p6V82A, and MA-
CAV82A, and their previously reported wild-type counterparts
(43, 44), particularly around the active-site region, suggesting
that the V82A mutation has not influenced substrate binding.
Conformational changes were observed, however, at the active
site between the inhibitorV82A structures and their previously
published wild-type counterparts (24, 55), suggesting that the
protease mutation has indeed influenced inhibitor binding. In
particular, the movement by the protease flaps in the RTVV82A
complex by more than 1 A˚ in comparison to the RTVWT
complex (24) is another indication of modified inhibitor bind-
ing. Difference distance plots show almost no shifts in the
backbone as a result of V82A on substrate recognition (Fig. 2a
and b) but show significant shifts in the inhibitor complexes
(Fig. 2c and d). Thus, the V82A mutation appears to minimally
perturb substrate binding while strongly affecting inhibitor
binding.
Protease-ligand hydrogen bonds are crucial for retaining the
stability of the complexes. The lack of difference in protease-
substrate hydrogen bonds between the substrateV82A and sub-
strateWT complexes (Fig. 3a) suggests that the specificity and
stability of protease-substrate complexes is unaltered. The
inhibitorV82A complexes, on the other hand, exhibit large-scale
shifts with respect to their wild-type complexes, resulting in a
loss of several hydrogen bonds. The substrates, which are
longer than inhibitors, form more extensive hydrogen bond
network with the protease, involving a variety of its residues
and encompassing the entire active site (Fig. 3b). This network
is probably a key factor in allowing the protease to maintain its
function despite having many mutations. Because inhibitors in
the inhibitorWT complexes have so few hydrogen bond accep-
tors and donors, the loss of hydrogen bonds due to the V82A
mutation further decreases the specificity and affinity of the
complex.
The asymmetric consensus volume occupied by the sub-
strates compared to the relatively symmetric inhibitors illus-
trates the crucial differences between them (Fig. 1c and d).
Coupled with our earlier findings with the wild-type protease-
substrate complexes (44), this observation supports the hy-
pothesis that the asymmetric toroidal shape on the unprimed
side of the substrate is important for substrate specificity. The
inhibitors, however, do not possess this shape (Fig. 1c). The
toroidal shape of the substrates is the only conserved structural
motif exhibited by the otherwise nonhomologous cleavage site
sequences and could be utilized in designing the next genera-
tion of inhibitors. In fact, the positions corresponding to the
P3–P1 sites of the substrates may be used to model inhibitors
instead of using the positions of P2–P2. A recent study has
revealed that inhibitors with a macrocyclic group connecting
the P3 and P1 residues are likely to be more efficient (35).
Since hydrophobic residues in HIV-1 protease have a higher
propensity for conferring drug-resistant mutations (54), a study
of changes in VDW interactions around the mutation site is
essential for understanding drug resistance. Lack of tight pack-
ing between the VDW surfaces of Val82/82 and the substrate,
seen in the substrateWT complexes, suggests that the valine
residue may not be extensively utilized during substrate bind-
ing (Fig. 4a). The similarity between the substrateWT and
substrateV82A complexes, particularly in relation to the VDW
packing of Ala82/82 with the substrates, is further supported
by the conservation of the estimated VDW interaction energy
(Table 2). On the other hand, the apposition of the VDW
surfaces of the Val82/82 residue and inhibitors (Fig. 4b) in the
inhibitorWT complexes suggests that the alanine mutation at
residue 82 will probably affect inhibitor binding. A previous
FIG. 4—Continued.
VOL. 77, 2003 DRUG RESISTANCE BY HIV-1 V82A PROTEASE 1313
 at UNIV O
F M
ASS M
ED SCH on August 4, 2008 
jvi.asm.org
D
ow
nloaded from
 
study using the V82A mutant in complex with a C2-symmetry-
based diol analogue, A-77003, pointed out that the protease is
highly adaptable to accommodating the valine-to-alanine alter-
ation (1). The present study, however, reveals substantial loss
of VDW packing on both sides of the active-site cleft when
residue 82 is an alanine in the inhibitorV82A complexes.
In addition, except for APV, all the drugWT complexes con-
tain six or more inhibitor atoms within VDW contact of the
Val82/82 residues (Fig. 4c). A drastic drop in this number is
observed near Ala82/82 in the case of the inhibitorV82A com-
plexes, while, with the exception of the p1–p6V82A complex,
almost no change is exhibited in the substrate structures. The
significant reduction in the p1–p6V82A complex (Fig. 4c) seems
to be compensated by new interactions triggered by subtle side
chain alterations by Asn (P2 of the p1–p6 substrate) and Val32
and Ile47 of the V82A protease. There is some indication,
although not an absolute correlation, that when the computed
buried surface area is large, as is the case for p1–p6, for the six
substrateWT complexes (44), the measured kcat/Km values is
small (11, 15, 52, 58). However, the relatively small kcat/Km of
p1–p6 (11, 15, 52, 58) of the isolated peptide is not critical for
viral maturation since the cleavage between nucleocapsid and
p1 (NC-p1) is observed to be the rate-determining step in the
processing of the polyproteins (42, 65). Among the inhibitors,
RTV in particular contains an isopropyl group at the tip of the
P3 site, which forms packing interactions with both CG1 and
CG2 of Val82 and, unlike all the other drugs and substrates, is
left substantially exposed when alanine is substituted for valine
(Fig. 4b). Also, the reduction in shape complementarity (30)
and the steep increase in the estimated VDW interaction en-
ergy (Table 2) lend further support to the notion that the
V82A mutation more probably affects inhibitor binding. The
fact that the corresponding values are almost unaltered in the
substrate structures, especially for the p1–p6 complexes (Table
2), provides further evidence that Val82 need not be exten-
sively utilized for substrate binding.
Kinetic assays for substrate cleavage and inhibitor binding
for both wild-type and V82A variants have been performed
extensively in other laboratories (11, 15, 18, 27, 32, 41, 52, 58).
A comparison of kinetic parameters for these protease variants
indicates only a moderate decrease in enzyme activity. The
kcat,V82A/kcat,WT ratios range from 1 to 0.5, while the Km,V82A/
Km,WT ratios range from 1 to 2 (18, 27). In contrast, the binding
of the inhibitors RTV, IDV, and NFV is more severely affected
by the mutation. The Ki,V82A/Ki,WT ratios range from 4.3 to
21.1, indicating that inhibition of V82A variant by these drugs,
relative to their inhibition of wild-type protease, is substantially
reduced (18, 27). These observations thus suggest that sub-
strate cleavage by the V82A variant is relatively less compro-
mised than the relative binding of the inhibitors IDV, NFV,
and RTV. These findings are consistent with the conclusions of
our structural analysis.
The structural analysis performed in this study of five ligand
complexes of HIV-1 protease V82A in comparison with their
wild-type counterparts elucidates the extent of adaptability
that is possible when a mutation confers drug resistance. As
drug therapy provides a selective pressure, HIV-1 protease will
mutate in such a manner as to maintain activity while resisting
the drugs. The implications of this study for future inhibitor
design are that it is crucial to use only residues that are vital to
substrate recognition as contact residues for new inhibitors.
Perhaps this type of directed inhibitor-design will make it more
difficult for further drug resistance to evolve.
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